Alexander Raskin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alexander Raskin has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Deepa Mokshagundam
Department of Cardiology, St. Louis Children's Hospital, St Louis, Missouri
2 shared publications - Joseph A. Spinner
Texas Children's Hospital Houston Texas USA
2 shared publications Katsuhide Maeda
Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
2 shared publications- Muhammad Shezad
The Heart Institute, Cincinnati Children's Hospital Medical Center
2 shared publications Othman Aljohani
UCSF Benioff Children's Hospital
2 shared publicationsScott Auerbach
Children's Hospital Colorado
2 shared publications
Latest Publications
- 21 May 2025
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 72 (1) , 65-70
Ventricular Assist Device Use in Pediatric Restrictive and Hypertrophic Cardiomyopathy: An ACTION Registry Analysis
The use of ventricular assist devices (VADs) in children with restrictive (RCM) and hypertrophic cardiomyopathy (HCM) remains rare. We describe the outcomes of patients with RCM and HCM supported by VAD in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry from March 2012 to December 2024. Thirty-four patients were identified: 20 left-sided VAD (LVAD), 13 biventricular VAD (BiVAD), and 1 total artificial heart (TAH). Median age at implant was 2.5 years (0.3–17.5), weight was 11.8 kg (4.5–81.8), and body surface area (BSA) was 0.54 m 2 (0.26–2.01). Diagnoses included RCM in 25 (73.5%) patients and HCM in 9 (26.5%). Illness severity at implant was high with 38.2% Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile 1, 41.2% on extracorporeal membrane oxygenation (ECMO), 52.9% on ventilator support, 88.2% treated with greater than or equal to 1 inotrope, and 52.9% supported with TPN. Four patients (11.8%) died on device, 25 (73.5%) were transplanted, 4 (11.8%) were alive on device, and 1 (2.9%) was transferred to another center. Patients who died all had HCM diagnosis, required BiVAD support, and experienced adverse events. The cause of death was inadequate support (1), infection (2), and multi-organ failure (1). Ventricular assist device support is a reasonable strategy for select RCM and HCM patients, although outcomes in HCM are less favorable.
- 21 May 2025
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 72 (1) , 65-70
Ventricular Assist Device Use in Pediatric Restrictive and Hypertrophic Cardiomyopathy: An ACTION Registry Analysis
The use of ventricular assist devices (VADs) in children with restrictive (RCM) and hypertrophic cardiomyopathy (HCM) remains rare. We describe the outcomes of patients with RCM and HCM supported by VAD in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry from March 2012 to December 2024. Thirty-four patients were identified: 20 left-sided VAD (LVAD), 13 biventricular VAD (BiVAD), and 1 total artificial heart (TAH). Median age at implant was 2.5 years (0.3–17.5), weight was 11.8 kg (4.5–81.8), and body surface area (BSA) was 0.54 m 2 (0.26–2.01). Diagnoses included RCM in 25 (73.5%) patients and HCM in 9 (26.5%). Illness severity at implant was high with 38.2% Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile 1, 41.2% on extracorporeal membrane oxygenation (ECMO), 52.9% on ventilator support, 88.2% treated with greater than or equal to 1 inotrope, and 52.9% supported with TPN. Four patients (11.8%) died on device, 25 (73.5%) were transplanted, 4 (11.8%) were alive on device, and 1 (2.9%) was transferred to another center. Patients who died all had HCM diagnosis, required BiVAD support, and experienced adverse events. The cause of death was inadequate support (1), infection (2), and multi-organ failure (1). Ventricular assist device support is a reasonable strategy for select RCM and HCM patients, although outcomes in HCM are less favorable.
- 18 January 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (4) , 530-540
The ACTION VAD registry: A collective five-year experience
- 18 January 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (4) , 530-540
The ACTION VAD registry: A collective five-year experience
- Open Access
Ventricular assist device implantation in children with a mechanical valve: An ACTION registry analysis
- Open Access
Current State of Pediatric Cardio-Oncology: A Review
The landscape of pediatric oncology has dramatically changed over the course of the past several decades with five-year survival rates surpassing 80%. Anthracycline therapy has been the cornerstone of many chemotherapy regimens for pediatric patients since its introduction in the 1960s, and recent improved survival has been in large part due to advancements in chemotherapy, refinement of supportive care treatments, and development of novel therapeutics such as small molecule inhibitors, chimeric antigen receptor T-cell therapy, and immune checkpoint inhibitors. Unfortunately, many cancer-targeted therapies can lead to acute and chronic cardiovascular pathologies. The range of cardiotoxicity can vary but includes symptomatic or asymptotic heart failure, arrhythmias, coronary artery disease, valvar disease, pericardial disease, hypertension, and peripheral vascular disease. There is lack of data guiding primary prevention and treatment strategies in the pediatric population, which leads to substantial practice variability. Several important future research directions have been identified, including as they relate to cardiac disease, prevention strategies, management of cardiovascular risk factors, risk prediction, early detection, and the role of genetic susceptibility in development of cardiotoxicity. Continued collaborative research will be key in advancing the field. The ideal model for pediatric cardio-oncology is a proactive partnership between pediatric cardiologists and oncologists in order to better understand, treat, and ideally prevent cardiac disease in pediatric oncology patients.
Open AccessCurrent State of Pediatric Cardio-Oncology: A Review
The landscape of pediatric oncology has dramatically changed over the course of the past several decades with five-year survival rates surpassing 80%. Anthracycline therapy has been the cornerstone of many chemotherapy regimens for pediatric patients since its introduction in the 1960s, and recent improved survival has been in large part due to advancements in chemotherapy, refinement of supportive care treatments, and development of novel therapeutics such as small molecule inhibitors, chimeric antigen receptor T-cell therapy, and immune checkpoint inhibitors. Unfortunately, many cancer-targeted therapies can lead to acute and chronic cardiovascular pathologies. The range of cardiotoxicity can vary but includes symptomatic or asymptotic heart failure, arrhythmias, coronary artery disease, valvar disease, pericardial disease, hypertension, and peripheral vascular disease. There is lack of data guiding primary prevention and treatment strategies in the pediatric population, which leads to substantial practice variability. Several important future research directions have been identified, including as they relate to cardiac disease, prevention strategies, management of cardiovascular risk factors, risk prediction, early detection, and the role of genetic susceptibility in development of cardiotoxicity. Continued collaborative research will be key in advancing the field. The ideal model for pediatric cardio-oncology is a proactive partnership between pediatric cardiologists and oncologists in order to better understand, treat, and ideally prevent cardiac disease in pediatric oncology patients.
- 11 April 2020
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 161 (4) , 1344-1345
Commentary: Is there life after cardiac death? Considering the challenges of heart donation after circulatory death
- 11 April 2020
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 161 (4) , 1344-1345
Commentary: Is there life after cardiac death? Considering the challenges of heart donation after circulatory death
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S222
Plasma Induced Transcriptional Analysis Assessment of Rejection in Pediatric Heart Transplantation
- 1 April 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (4) , S222
Plasma Induced Transcriptional Analysis Assessment of Rejection in Pediatric Heart Transplantation